Zhejiang Hisun Pharmaceutical Co Ltd Market Cap ($2.27 Billion)
Market Cap & Net Worth: Zhejiang Hisun Pharmaceutical Co Ltd (600267)
Zhejiang Hisun Pharmaceutical Co Ltd market cap. Zhejiang Hisun Pharmaceutical Co Ltd (SHG:600267) has a market capitalization of $2.27 Billion (CN¥15.52 Billion) as of November 1, 2026. Listed on the SHG stock exchange, this China-based company holds position #5522 globally and #930 in its home market, demonstrating a -5.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Hisun Pharmaceutical Co Ltd's stock price CN¥12.95 by its total outstanding shares 1198761196 (1.20 Billion). Also see 600267 operating cash flow for how efficiently the company converts equity into cash flow.
Zhejiang Hisun Pharmaceutical Co Ltd Market Cap History (2015–2026)
Zhejiang Hisun Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $2.66 Billion to $2.27 Billion (0.22% CAGR). Check 600267 stock price for real-time trading data and today's change.
Zhejiang Hisun Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Hisun Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Zhejiang Hisun Pharmaceutical Co Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.16x
Zhejiang Hisun Pharmaceutical Co Ltd's market cap is 0.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.21x
Zhejiang Hisun Pharmaceutical Co Ltd's market cap is 3.21 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.22 Billion | $9.73 Billion | -$94.43 Million | 0.23x | N/A |
| 2017 | $2.57 Billion | $10.57 Billion | $13.57 Million | 0.24x | 189.30x |
| 2018 | $1.43 Billion | $10.19 Billion | -$492.47 Million | 0.14x | N/A |
| 2019 | $1.69 Billion | $11.07 Billion | $93.07 Million | 0.15x | 18.12x |
| 2020 | $2.82 Billion | $11.35 Billion | $417.19 Million | 0.25x | 6.76x |
| 2021 | $2.40 Billion | $12.14 Billion | $486.89 Million | 0.20x | 4.92x |
| 2022 | $1.91 Billion | $12.04 Billion | $488.86 Million | 0.16x | 3.90x |
| 2023 | $1.64 Billion | $10.37 Billion | -$93.17 Million | 0.16x | N/A |
| 2024 | $1.46 Billion | $9.79 Billion | $601.18 Million | 0.15x | 2.42x |
| 2025 | $1.73 Billion | $10.55 Billion | $540.71 Million | 0.16x | 3.21x |
Competitor Companies of 600267 by Market Capitalization
Companies near Zhejiang Hisun Pharmaceutical Co Ltd in the global market cap rankings as of November 1, 2026. Also see Zhejiang Hisun Pharmaceutical Co Ltd (600267) total assets for a full breakdown of the balance sheet.
Key companies related to Zhejiang Hisun Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Zhejiang Hisun Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Zhejiang Hisun Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Zhejiang Hisun Pharmaceutical Co Ltd's market cap moved from $2.66 Billion to $ 2.27 Billion, with a yearly change of 0.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.27 Billion | +30.94% |
| 2025 | CN¥1.73 Billion | +19.16% |
| 2024 | CN¥1.46 Billion | -11.32% |
| 2023 | CN¥1.64 Billion | -13.87% |
| 2022 | CN¥1.91 Billion | -20.45% |
| 2021 | CN¥2.40 Billion | -15.06% |
| 2020 | CN¥2.82 Billion | +67.34% |
| 2019 | CN¥1.69 Billion | +18.12% |
| 2018 | CN¥1.43 Billion | -44.41% |
| 2017 | CN¥2.57 Billion | +15.62% |
| 2016 | CN¥2.22 Billion | -16.52% |
| 2015 | CN¥2.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Zhejiang Hisun Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.27 Billion USD |
| MoneyControl | $2.27 Billion USD |
| MarketWatch | $2.27 Billion USD |
| marketcap.company | $2.27 Billion USD |
| Reuters | $2.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mol… Read more